Depression Screening from Voice Samples of Patients Affected by Parkinson’s Disease

Abstract

Depression is a common mental health problem leading to significant disability worldwide. It is not only common but also commonly co-occurs with other mental and neurological illnesses. Parkinson’s disease (PD) gives rise to symptoms directly impairing a person’s ability to function. Early diagnosis and detection of depression can aid in treatment, but diagnosis typically requires an interview with a health provider or a structured diagnostic questionnaire. Thus, unobtrusive measures to monitor depression symptoms in daily life could have great utility in screening depression for clinical treatment. Vocal biomarkers of depression are a potentially effective method of assessing depression symptoms in daily life, which is the focus of the current research. We have a database of 921 unique PD patients and their self-assessment of whether they felt depressed or not. Voice recordings from these patients were used to extract paralinguistic features, which served as inputs to machine learning and deep learning techniques to predict depression. The results are presented here, and the limitations are discussed given the nature of the recordings which lack language content. Our models achieved accuracies as high as 0.77 in classifying depressed and nondepressed subjects accurately using their voice features and PD severity. We found depression and severity of PD had a correlation coefficient of 0.3936, providing a valuable feature when predicting depression from voice. Our results indicate a clear correlation between feeling depressed and PD severity. Voice may be an effective digital biomarker to screen for depression among PD patients.

The role of machine learning in clinical research: transforming the future of evidence generation

“…Using the relatively large and complex data yielded by wearables and other devices for research purposes therefore requires specialized data collection, storage, validation, and analysis techniques [ 34 – 37 ]. For instance, a deep neural network was used to process input from a mobile single-lead electrocardiogram platform [ 38 ], a random forest model was used to process audio output from patients with Parkinson’s disease [ 39 ], and a recurrent neural network was used to process accelerometer data from patients with atopic dermatitis [ 40 ]. These novel digital biomarkers may facilitate the efficient conduct and patient-centeredness of clinical trials, but this approach carries potential pitfalls.…”

Detection of dementia on voice recordings using deep learning: a Framingham Heart Study

“…Digital health technologies in general and voice in particular are increasingly being evaluated as potential screening tools for depression [ 18 – 21 ] and various neurodegenerative diseases such as Parkinson’s disease [ 22 – 25 ]. Recently, potential opportunities for developing digital biomarkers based on mobile/wearables for AD were outlined [ 26 , 27 ].…”

The Digital Neurologic Examination

“…An array of digital biomarkers of disease may also provide valuable insights into patient affect and behavior. For example, vocal biomarkers from voice recordings provide both linguistic and paralinguistic features for which machine learning techniques may be used to identify and monitor depression [35]. Further, autonomic physiological (heart rate, respiratory rate, skin temperature) digital biomarkers, another exploratory area of digital health, collected from varied wearables may identify stress or anxiety levels [36].…”